|
Click Here
for Recommended Books
If you would like to search for a particular product please
do so by typing it in the search box below.
Go Directly To Store
View/Buy From Product List
View Basket Contents
Monthly Specials
Personal Training
Newsletter Archive
Amino Acids
Anti-Aging/Cardiovascular
Anti-inflammatory/Joint Health
Cancer Adjuvant
Therapies
Cookies
Energy
Female/Osteoporosis
Fiber/Cholesterol
Lowering
Fish Oils
Gift Baskets
Herbs
Hormones
Immune Function
Minerals
Miscellaneous
Protein Bars
Protein Powders
Sexual Enhancement
Skin Care
Sports Supplements
Stevia
Vitamins
Weight Management
Weight Training
Accessories
View Catalog
Healthy Links
| |
LE1252
Super
Bioactive CoQ10 with Ubiquinol 50 mg. 100 softgels
$43.50
Buy Me
When it comes to choosing a CoQ10 supplement, the primary factor is how many
swallowed milligrams actually make it into your bloodstream. Coenzyme Q10 is a
notoriously difficult nutrient to absorb. A recent study showed that in
seriously ill patients, conventional ubiquinone CoQ10 was hardly detectable in
the blood, whereas the new ubiquinol resulted in significant blood level
increases and subsequent clinical improvements.
Scientific studies show that ubiquinol absorbs up to 8 times greater than
ubiquinone and that higher levels of ubiquinol remain in the blood far
longer than ubiquinone. In studies measuring exercise-induced fatigue,
ubiquinol was 90% more effective than ubiquinone. In middle-aged mice,
ubiquinol was shown to be 40% more effective in slowing measurements of aging
compared to ubiquinone.1
Japanese researchers have developed a novel ubiquinol delivery system that has
been shown to double-peak CoQ10 blood levels (i.e.,100% greater peak absorption)
in mice compared to the original ubiquinol formula. This enhanced ubiquinol
formula also achieved a 66% greater amount of CoQ10 in blood over 24 hours
compared to the original formula.2 Life Extension has been issued an exclusive
license to distribute this enhanced-absorbing ubiquinol.
More humans are supplementing with coenzyme Q10 than ever before. One reason is
the increased awareness that the "statin" drugs used to lower LDL and
cholesterol depletes the body of CoQ10. What most doctors don't know, however,
is that normal aging may result in a greater reduction in CoQ10 than is caused
by taking statin drugs. For example, while statin drugs have been shown to
reduce plasma CoQ10 by 40%,3 the aging process reduces CoQ10 levels in the heart
muscle wall by 72%.4 What is particularly frightening is the thought of people
taking statin drugs who fail to supplement with CoQ10. The CoQ10 deficit caused
by the dual affects of aging5 and statin drug use could result in severe
depletion of cellular vitality.
References
1. Yan J et al. Exp Gerontol 2006 Feb;41(2):130-40.
2. Schulz C et al. Regul Toxicol Pharmacol. 2006 Aug 17; 57(7-8):546-55.
3. Ghirlanda G et al. J Clin Pharmacol. 1993 Mar;33(3):226-9.
4. Rosenfeldt FL et al. Biofactors. 1999;9(2-4):291-9.
5. Kalen A, Appelkvist E, Dallner G. Lipids and Aging. 1989; 24(7):579-84.
More Information on CoQ10
CoQ10 is required to convert fats and sugars into cellular energy, yet the
natural production of CoQ10 declines precipitously with advancing age.3 When the
body has an ample amount of CoQ10 the mitochondria can work most efficiently
throughout the entire body, in cells everywhere, including the most densely
populated area, the heart.4
Coenzyme Q10 is incorporated into the mitochondria of cells throughout the
body where it facilitates and regulates the transformation of fats and sugars
into energy. A large body of scientific evidence shows that CoQ10’s ability to
restore mitochondrial function has a profound effect on one’s overall health.28*
As people age, their natural synthesis of CoQ10 slowly declines. When people
take “statin” cholesterol lowering drugs, CoQ10 synthesis can be reduced even
further.29,30
With the availability of this highly absorbable coenzyme Q10, it becomes much
more affordable to supplement with greater doses. For those seeking the higher
doses now being recommended by more scientists, one of the new emulsified 30 mg
capsules would provide an efficient and economic method of increasing blood
levels of coenzyme Q10.
*Effect of Statin Drug on Coenzyme Q10 Plasma Levels
In a study at Columbia University College of Physicians and Surgeons in New
York, 45 subjects, including men and women, with elevated low-density
lipoprotein (LDL) levels (thus at risk for cardiovascular disease) received 80
milligrams of oral atorvastatin for thirty days. After two weeks and at the
study's conclusion, the participants were examined for changes in liver enzymes,
kidney function and any adverse effects, including muscle pain or weakness.
Plasma levels of coenzyme Q10 were measured at the beginning of the study, and
at 14 and 30 days.
In all participants, coenzyme Q10 levels were lower at both fourteen and
thirty days than at the beginning of the study. Following two weeks of treatment
with atorvastatin , plasma coenzyme Q10 levels in thirty-two participants were
reduced by 49 percent. After thirty days, the mean coenzyme Q10 concentration
was reduced from 1.26 micrograms per milliliter to 0.62 micrograms per
milliliter.
The findings could explain the most common adverse effects of statins,
particularly muscle pain, exercise intolerance and myoglobinuria. The authors
recommend that, “it may be reasonable to add coQ10 in patients receiving
long-term treatment with statins in general, and atorvastatin in particular.
This recommendation is strengthened by the general experience that oral
coQ10—even in high doses—is well tolerated by patients.” ( Rundek T et al, “
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk
for cardiovascular disease and stroke,” Arch Neur , vol 16, June 2004, p
884-92.)
Supplement Facts
|
Serving Size: 1 capsule |
|
Servings per container: 100 |
|
Amount per Serving |
|
Calories |
3 |
|
Calories from fat |
3 |
|
Total fat |
0.3 g |
|
Ubiquinol (Kaneka QH™ reduced form of CoQ10) |
50 mg |
|
Other ingredients: safflower oil, gelatin, glycerin,
beeswax, lecithin, water, polyglycerol fatty acid ester, caramel color.
Contains soybeans. This product contains NO milk, egg,
fish, peanuts, crustacean shellfish (lobster, crab, shrimp), tree nuts,
wheat, yeast, gluten, corn, or rice. Contains NO sugar, and no artificial
sweeteners, flavors, or preservatives.
|
Kaneka QH™ is a trademark of Kaneka Corporation.
Dosage and Use
-
Suggested dose is one to two softgel(s) daily for
those over age 30.
-
For best utilization, take softgels with room
temperature water after a meal.
Warnings
-
Keep out of reach of children.
-
Do not exceed recommended dose.
-
If you have a bad reaction to this product,
discontinue use.
-
When using nutritional supplements, please inform
your physician if you are undergoing treatment for a medical condition or if
you are pregnant or lactating.
Warning: These products are not intended to diagnose, treat, cure or prevent
any disease. Please consult with a healthcare professional before starting any
diet or exercise program. Some of these products are not recommended for
individuals under the age of 18.
References
Heart Health
1. Circulation. 2000 Oct 31;102(18):2284-99.
2. Biofactors. 1999;9(2-4):371-8.
3. Lipids. 1989 Jul;24(7):579-84.
4. Mol Aspects Med. 1994;15 Suppl:s165-75.
5. Science. 1982 Sep 24;217(4566):1214-22.
6. Ann West Med Surg. 1951;5:825-9.
7. Ann West Med Surg. 1951;5:830-55.
8. Ann West Med Surg. 1951;5:856-62.
9. JAMA. 1951;145:1232-6.
10. Am J Dig Dis. 1952;19:381-4.
11. J Nutr. 2003 Dec;133(12):4135-8.
12. J Nutr. 2003 May;133(5):1291-5.
13. Am J Clin Nutr. 2002 Nov;76(5):961-7.
14. Br J Clin Pharmacol. 2002 Aug;54(2):140-6.
15. Kidney Int. 2002 Mar;61(3):1040-6.
16. An Esp Pediatr. 1993 Jul;39(1):37-41 (in Spanish).
17. Metabolism. 1985 Dec;34(12):1115-21.
18. N Engl J Med. 1983 Aug 25;309(8):448-53.
19. Biochemistry. 1999 Oct 19;38(42):13991-8.
20. Atherosclerosis. 1995 Dec;118 Suppl:S1-5.
21. Int J Clin Pract Suppl. 2002 Jul;(130):15-9.
22. Curr Atheroscler Rep. 2004 Jan;6(1):73-8.
23. Phytomedicine. 2004 Feb;11(2-3):105-13.
24. Farmaco. 1995 Sep;50(9):595-9.
25. Lipids. 2004 Feb;39(2):143-51.
26. Anticancer Res. 2004 Mar-Apr;24(2B):563-9.
27. Toxicol Lett. 2000 Mar 15;112-113:499-505.
28. J Pharm Pharmacol. 1997 Jan;49(1):105-7.
29. Biochem Pharmacol. 1999 Oct 1;58(7):1167-72.
30. Prostaglandins Leukot Essent Fatty Acids. 1995 Apr;52(4):223-7.
31. Thromb Res. 1985 Nov 1;40(3):413-7.
32. Planta Med. 1998 May;64(4):353-6.
33. Eur J Drug Metab Pharmacokinet. 2001 Oct-Dec;26(4):241-7.
34. Eur J Clin Pharmacol. 1991;41(6):615-7.
35. Prostaglandins Leukot Essent Fatty Acids. 1998;58:61-64.
36. Pharmacol Res. 1997;36:293-297.
37. Int J Clin Pharmacol Res. 1996; 16:67-72.
38. Pharmacol Res. 1996;34:181-185.
39. Drugs Res Devel. 2002;3:159-172.
40. Int J Clin Pharmacol Res. 2001;21:31-41.
41. Gynecol Endocrinol. 2000; 14:187-195.
42. Int J Tissue React. 1999;21:85-92.
43. Int J Clin Pharmacol Res. 1999;19:105-116.
44. Clin Pharmacol Ther. 1999;65:439-447.
45. Diabetes Care. 1995;18:393-397.
46. Curr Ther Res. 1992;52:507-513.
47. Nutr Rev. 2003 Nov;61(11):376-83.
48. J Med Food. 2001;4:71-77.
49. Br J Clin Pharmacol. 2000;50:255-262.
50. Physiol Behav. 1999;67:1-7.
51. Arch Med Res. 1997;28:355-360.
52. Drugs Res Devel. 2002;3:159-172.
53. Curr Ther Res. 1999;60: 458-467.
54. Int J Clin Pharm Res. 1994; 14:27-33.
55. Am J Med. 2003 Sep;115(4):265-71.
56. J Am Geriatr Soc. 2003 Jul;51(7):991-6.
57. Arch Intern Med. 2003 Jul 14;163(13):1549-54.
58. Transplantation. 2004 Jun 27;77(12):1848-53.
59. Clin Appl Thromb Hemost. 2001 Jan;7(1):53-7.
60. Am J Obstet Gynecol. 2000 Sep;183(3):523-8.
61. J Am Dent Assoc. 2000 Mar;131(3):331-5.
62. Curr Opin Obstet Gynecol. 1995 Apr;7(2):135-9.
63. Hum Reprod. 1994 Oct;9(10):1954-7.
64. Am J Obstet Gynecol. 1993 Apr;168(4):1083-91; discussion 1091-3.
65. Res Commun Chem Pathol Pharmacol. 1991 Nov;74(2):153-65.
66. Circulation. 2003 Oct 7;108(14):1673-5. Epub 2003 Sep 22.
67. Ital Heart J. 2001 Aug;2(8):582-8.
68. J Thromb Haemost. 2004 Nov;2(11):1934-1940.
69. Chest. 2004 May;125(5):1610-5.
70. Ann Pharmacother. 2003 Nov;37(11):1593-7.
71. J Thromb Thrombolysis. 2002 Oct;14(2):145-50.
72. Chem Drug. 1972 Aug 5;198:196-7.
73. Zhonghua Nei Ke Za Zhi. 1995 Sep;34(9):595-8 (in Chinese).
74. Lancet. 1973 May 5;1(7810):979.
75. Arch Intern Med. 2000 Nov 13;160(20):3123-7.
76. N Engl J Med. 2002 Sep 26;347(13):969-74. Summary for patients in: CMAJ.
2002 Oct 29;167(9):1036.
77. Planta Med. Jun 1990, 56 (3) p249-53
78. Med Hypotheses. 1980 Nov;6(11):1123-33.
79. In Vivo. 1999 Jan-Feb;13(1):7-12.
80. Biochem Pharmacol. 1999 Oct 1;58(7):1167-72.
81. Prostaglandins Leukot Essent Fatty Acids. 1995 Apr;52(4):223-7.
82. Indian J Med Res. 1969;57(10):1950-62.
83. J Assoc Physicians India. 1989;37(5):323-8.
84. Econ Med Plant Res. 1991;5:48-82.
85. Planta Med. 1979;37:367-9.
86. Cardiovasc Drugs Ther. 1994 Aug;8(4):659-64.
87. Indian J Med Res. 1988 Apr;87:356-60.
88. Indian J. Med. Res. 1979; 70(6):992-996.
89. Indian J Med. 1988;87:327-35.
90. Thromb Res. 2003;111(4-5):259-65.
91. Prostaglandins Leukot Essent Fatty Acids. 2002 Dec;67(6):475-8.
92. Indian J Med Sci. 2001 Feb;55(2):83-6.
93. J Nutr. 2000 May;130(5):1124-31.
94. Indian J Med Res. 1993 Oct;98:240-2.
|
